Focus on Metabolism
We're committed to discovering and developing innovative medicines for metabolic diseases. So we focus on creating new treatment options for patients with diabetes, as well as ways to prevent major adverse cardiovascular events in patients with acute coronary syndrome.
While care has improved dramatically over recent years, more than two thirds of cardiovascular events still aren't prevented. As we've developed a deeper understanding of heart disease, research has shown that inflammation plays a central role in the growth and rupture of arterial plaques, which can lead to a coronary event such as heart attack or stroke. We've also seen that lower serum LDL may play a role in reducing the incidence of coronary heart disease. We hope to prevent cardiovascular events by interfering with the inflammation cascade or by impacting LDL target levels.
Recent PublicationsPLoS One, February 2013
Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.
View Article Journal of Biological Chemistry, November 2012
Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low-density lipoprotein receptor and serum cholesterol levels.
View Article Science Translational Medicine, December 2011
Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1.